Enjoy complimentary customisation on priority with our Enterprise License!
Some of the key findings from this pericarditis drugs market forecast report are summarized below
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Clinical trials on the combination of aspirin and colchicine have shown significant results in reducing the recurrence rate of idiopathic pericarditis in patients compared to conventional monotherapy. Dual therapy also had a significant impact on lowering the symptoms of pericarditis at a 72-hour interval without any side effects. Such advantages have increased the adoption of dual therapy for the treatment of recurrent pericarditis. Moreover, the rising prevalence of idiopathic pericarditis is also anticipated to increase the demand for dual therapy. This will subsequently drive the growth of the global pericarditis drugs market size during the forecast period.
Additionally, the advent of biologics is also one of the major factors that will fuel the growth of the pericarditis drugs market size. Anakinra was traditionally used for the treatment of rheumatoid arthritis. The drug is also approved by the US FDA for the treatment of various other diseases including colchicine-resistant familial Mediterranean fever (FMA) and tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Moreover, pericarditis is considered as the most common indication of FMF and TRAPS and the use of anakinra is effective in reducing recurrent pericarditis episodes. More detailed studies on the use of anakinra coupled with the adoption of dual therapy, will drive global pericarditis drugs market at a CAGR of over 4% during 2019-2023.
The global pericarditis drugs market is fairly fragmented. This research report provides a detailed analysis of the market’s competitive landscape and provides information on the products offered by various companies. Key insights provided by this pericarditis drugs market report will help companies create effective strategies to improve their revenue share.
The report offers a detailed analysis of several leading companies including:
NSAIDs will account for the largest pericarditis market share. The high therapeutic efficacy, abundant availability, and the affordability of NSAID drugs are driving the growth of this market segment. Moreover, the use of NSAID drugs such as naproxen as an alternative for the treatment of pericarditis and related comorbidities will also contribute to the growth of the market in this segment.
North America will provide the largest growth opportunities for pericarditis drug companies. The strong prevalence of pericarditis in patients with cardiovascular diseases has increased the demand for pericarditis drugs in the region. The increased expenditure on healthcare in the US and the rising investments in the R&D by large pharmaceutical vendors will also contribute to the growth of the pericarditis drugs market size in North America.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
PART 14: APPENDIX
PART 15: EXPLORE TECHNAVIO
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.